Novaseek Research Receives Start up Challenge Award From the Pistoia Alliance

BOSTON, MA--(Marketwired - Oct 14, 2015) - Novaseek Research, an innovator in clinical data and biospecimens for research, today announced that it was selected as a finalist for the prestigious Pistoia Alliance President's Startup Challenge 2015. Novaseek provides life science industry and academia with access to real-world real-time human biospecimens and associated clinical data in compliance with HIPAA.

The Pistoia Alliance is a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D. The Startup Challenge 2015 panel of expert judges, drawn from the Pistoia Alliance's membership, evaluated more than 30 start-up companies from around the world who are developing new ideas to lower the barriers to innovation in life sciences R&D.

"We are thrilled to be a selected as a finalist of this prestigious award for our innovative approach to providing access to clinical data and human biospecimens to R&D organizations," said Kate Torchilin, CEO, Novaseek Research. "We will further utilize the award and collaboration with Pistoia Alliance to solve a major industry bottleneck of sourcing clinically annotated tissue specimens, in addition to biofluids. Also, via our Clinical Data Network for Research (CDNR) platform, we will greatly increase the number of hospitals participating in biospecimen collections."

Today, industry and academia need access to clinical data and biospecimens to accelerate discovery and translational studies. However, identifying the right patient at the right time, and getting access to biospecimens and data, has been a chronic problem that continues to delay or derail vital research and development projects. Novaseek's CDNR platform resolves these problems by enabling researchers to efficiently and effectively incorporate clinical data and biospecimens into their discovery programs.

The CDNR platform is currently available to early adopters in industry, academia and government. Preferential CDNR license terms are offered until the end of year 2015. Requests should be send to: info@novaseekresearch.com

About Novaseek

Novaseek is transforming how biomedical researchers access clinical data and human biospecimens to accelerate R&D. The Novaseek Clinical Data Network for Research (CDNR) is the industry's first comprehensive platform enabling researchers to access real-world, real-time clinical data and large quantities of high quality biospecimens - that is essential for understanding disease and developing medical advances -- all in compliance with HIPAA. Incorporating Novaseek's CDNR platform across all phases of research and development helps industry and academia generate powerful new insights, increases R&D productivity and decreases risk in the pursuit of new cures. The CDNR platform was developed by experts in drug development, hospital operations and health IT to create a win-win for industry, academia, healthcare providers and patients. For more information, please visit www.novaseekresearch.com